Feasibility of FDG-PET Scan before Second Look Operation in Patients with Ovarian Cancer.
- Author:
Won Ho JUNG
1
;
Mu Sam KANG
;
Chun Suk PARK
;
Mun Hong KIM
;
Sung Il KIM
;
Seok Chul CHOI
;
Sang Young RYU
;
Kyung Hee LEE
Author Information
1. Department of Obstetrics and Gynecology, Korea Cancer Center Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
FDG-PET scan;
Ovarian carcinoma;
Second-look operation
- MeSH:
Abdomen;
Biopsy;
Cystadenocarcinoma, Serous;
Drug Therapy, Combination;
Humans;
Laparotomy;
Lung;
Neoplasm, Residual;
Ovarian Neoplasms*;
Pelvis;
Positron-Emission Tomography
- From:Korean Journal of Obstetrics and Gynecology
2002;45(10):1765-1769
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: This study is to investigate whether Positron Emission Tomography (PET) is useful for determining pathologic complete response in patients with ovarian carcinoma who had a clinical complete response after primary treatment. METHODS: FDG-PET scans were performed in 10 patients with advanced ovarian cancer (4 patients with stage IIC, 6 patients with IIIC), who showed complete response with cytoreductive surgery and 6 cycles of post-operative adjuvant Cisplatin-based combination chemotherapy. FDG-PET scan was obtained with GE Advance Scanner, beginning at 50 minutes after injection of 370-555 MBq (10-15 mCi) of 18F FDG. Uptakes exceeding 3.5 SUV (Standardized Uptake Value) or larger than surrounding tissue were determined as a positive findings. Second-look laparotomy was undertaken within median 4 days after FDG-PET scanning. RESULTS: The mean age of the patients was 45 years and serous cystadenocarcinoma was most common histologic type. None showed active lesion in pelvis or abdomen with FDG-PET scan (SUV: >3.5 kg/ml), however, 5 patients (50%) showed residual tumors on multiple biopsy during second look operation. One patient showed positive lesion in lung on FDG-PET scan, which was confirmed to have metastatic lesion. CONCLUSION: FDG-PET scan is not useful for detection of small ovarian cancer lesions in pelvis and abdomen and cannot substitute for second-look operation to determine pathologic complete response.
